Abstract
Metastasis is a major cause of morbidity and mortality in patients with cancer. The molecular mechanisms that control metastasis are related to alterations in various oncogenes, tumor suppressor genes, metastasis suppressor genes, and growth factors and their receptors. These abnormalities affect the downstream signal transduction pathways involved in the control of cell growth and other malignant properties. One of the most recognized signal transduction pathways involves the signal transducer and activator of transcription 3 (STAT3) protein. STAT3, known to be activated by numerous cytokines, growth factors, and oncogenic proteins, is constitutively phosphorylated in several clinical cancer specimens and cell lines, leading to cell transformation and tumorigenesis. STAT3 target genes are involved in multiple steps of metastasis, including invasion, cell survival, self-renewal, angiogenesis, and tumor-cell immune evasion. Furthermore, the inhibition of STAT3 by a variety of mechanisms can exert anti-tumor and anti-metastasis effects. These findings suggest that STAT3 might be an excellent target for therapeutic intervention in tumor metastases. This review highlights the pivotal role of STAT3 in tumor metastases and in therapeutic strategies to target the STAT3 signaling pathway for the inhibition of metastases.
Keywords: Transcription factor, STAT3, Metastasis, Invasion, Angiogenesis
Current Molecular Medicine
Title: STAT3 as a Central Regulator of Tumor Metastases
Volume: 9 Issue: 5
Author(s): Eswaran Devarajan and Suyun Huang
Affiliation:
Keywords: Transcription factor, STAT3, Metastasis, Invasion, Angiogenesis
Abstract: Metastasis is a major cause of morbidity and mortality in patients with cancer. The molecular mechanisms that control metastasis are related to alterations in various oncogenes, tumor suppressor genes, metastasis suppressor genes, and growth factors and their receptors. These abnormalities affect the downstream signal transduction pathways involved in the control of cell growth and other malignant properties. One of the most recognized signal transduction pathways involves the signal transducer and activator of transcription 3 (STAT3) protein. STAT3, known to be activated by numerous cytokines, growth factors, and oncogenic proteins, is constitutively phosphorylated in several clinical cancer specimens and cell lines, leading to cell transformation and tumorigenesis. STAT3 target genes are involved in multiple steps of metastasis, including invasion, cell survival, self-renewal, angiogenesis, and tumor-cell immune evasion. Furthermore, the inhibition of STAT3 by a variety of mechanisms can exert anti-tumor and anti-metastasis effects. These findings suggest that STAT3 might be an excellent target for therapeutic intervention in tumor metastases. This review highlights the pivotal role of STAT3 in tumor metastases and in therapeutic strategies to target the STAT3 signaling pathway for the inhibition of metastases.
Export Options
About this article
Cite this article as:
Devarajan Eswaran and Huang Suyun, STAT3 as a Central Regulator of Tumor Metastases, Current Molecular Medicine 2009; 9(5) . https://dx.doi.org/10.2174/156652409788488720
DOI https://dx.doi.org/10.2174/156652409788488720 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |

- Author Guidelines
- Editorial Policies
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Allegations from Whistleblowers
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Reviewer Guidelines
- Guest Editor Guidelines
- Board Recruitment Workflow
- Short Guide for New Editors
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Current Phthalocyanines Delivery Systems in Photodynamic Therapy: An Updated Review
Current Medicinal Chemistry Soluble Epoxide Hydrolase Inhibitors and their Potential for Treatment of Multiple Pathologic Conditions
Current Medicinal Chemistry Mammaglobin-Based Strategies for Treatment of Breast Cancer
Current Cancer Drug Targets In vivo Real-Time Near-Infrared Fluorescent Mapping of Sentinel Lymph Nodes Using Methylene Blue Encapsulated in a Microemulsion Nanosystem
Current Nanoscience Synergistic Enhancement of Cancer Therapy Using a Combination of Fusion Protein MG7-scFv/SEB and Tumor Necrosis Factor Alpha
Protein & Peptide Letters Progresses in TCM Metal-Based Antitumour Agents
Anti-Cancer Agents in Medicinal Chemistry Recent Patents of DNA Methylation Biomarkers in Gastrointestinal Oncology
Recent Patents on DNA & Gene Sequences A Network Pharmacology Approach to Reveal the Underlying Mechanisms of Zuogui Yin in the Treatment of Male Infertility
Combinatorial Chemistry & High Throughput Screening Epigenetics in Cystic Fibrosis: Epigenetic Targeting of a Genetic Disease
Current Drug Targets Polymorphisms of Human N-Acetyltransferases and Cancer Risk
Current Drug Metabolism Anti-cancer Research on Arnebiae radix-derived Naphthoquinone in Recent Five Years
Recent Patents on Anti-Cancer Drug Discovery Is the Epithelial-to-Mesenchymal Transition Clinically Relevant for the Cancer Patient?
Current Pharmaceutical Biotechnology A Structural Insight into Hydroxamic Acid Based Histone Deacetylase Inhibitors for the Presence of Anticancer Activity
Current Medicinal Chemistry The Human L1 Element: A Potential Biomarker in Cancer Prognosis, Current Status and Future Directions
Current Molecular Medicine Comprehensive Review of Cancer Chemopreventive Agents Evaluated in Experimental Carcinogenesis Models and Clinical Trials
Current Medicinal Chemistry PTD/CPP Peptide-Mediated Delivery of siRNAs
Current Pharmaceutical Design Anti-Inflammatory Drugs and Prediction of New Structures by Comparative Analysis
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Immune Receptors, Cadherins and their Interactions
Current Immunology Reviews (Discontinued) PHB in Cardiovascular and Other Diseases: Present Knowledge and Implications
Current Drug Targets Alternative Splicing, DNA Damage and Modulating Drugs in Radiation Therapy for Cancer
Anti-Cancer Agents in Medicinal Chemistry